In the run-up to its scheduled R&D presentation on Monday, Uniqure NV produced what H.C. Wainwright's Debjit Chattopadhyay dubbed "a compelling glimpse" of the future of hemophilia B treatment, positioning AMT-061 "to be not only the best-in-class one-and-done solution, but also, the first to market."